SAMHD1 is the dendritic– and myeloid–cell–specific HIV–1 restriction factor counteracted by Vpx

doi:10.1038/nature10117

Nature. Author manuscript; available in PMC 2013 March 13.

Published in final edited form as:

Nature. 2011 May 25; 474(7353): 654–657.

doi: 10.1038/nature10117

PMCID: PMC3595993

EMSID: EMS51882

SAMHD1 is the dendritic– and myeloid–cell–specific HIV–1 restriction factor counteracted by Vpx

Nadine Laguette,¹ Bijan Sobhian,¹ Nicoletta Casartelli,² Mathieu Ringeard,¹ Christine Chable-Bessia,¹ Emmanuel Ségéral,³ Ahmad Yatim,¹ Stéphane Emiliani,³ Olivier Schwartz,² and Monsef Benkirane¹

¹Institut de Génétique Humaine, Laboratoire de Virologie Moléculaire, CNRS UPR1142, Montpellier 34000 France

²Institut Pasteur, Virus and Immunity Unit, URA CNRS 3015, Paris, France

³Institut Cochin, Université Paris Descartes, CNRS UMR 8104 INSERM U567, Paris, France

Correspondence and requests for materials should be addressed to M.B. (Email: monsef.benkirane/at/igh.cnrs.fr) or N.L. (Email: nadine.laguette/at/igh.cnrs.fr).

Author Contributions M.B. and N.L. conceived the study and wrote the paper. M.B. and N.L. designed experiments and interpreted data. O.S. designed some experiments, interpreted data and edited the paper. N.L., B.S., N.C. and M.R. designed and performed experiments. C.C.-B. and E.S. provided technical assistance. N.L., B.S., N.C., M.B., A.Y., S.E. and O.S. discussed the data.

The publisher's final edited version of this article is available at Nature

See other articles in PMC that cite the published article.

Abstract

The primate lentivirus auxiliary protein Vpx counteracts an unknown restriction factor that renders human dendritic and myeloid cells largely refractory to HIV-1 infection^1-6. Here we identify SAMHD1 as this restriction factor. SAMHD1 is a protein involved in Aicardi–Goutières syndrome, a genetic encephalopathy with symptoms mimicking congenital viral infection, that has been proposed to act as a negative regulator of the interferon response⁷. We show that Vpx induces proteasomal degradation of SAMHD1. Silencing of SAMHD1 in non-permissive cell lines alleviates HIV-1 restriction and is associated with a significant accumulation of viral DNA in infected cells. Concurrently, overexpression of SAMHD1 in sensitive cells inhibits HIV-1 infection. The putative phosphohydrolase activity of SAMHD1 is probably required for HIV-1 restriction. Vpx-mediated relief of restriction is abolished in SAMHD1-negative cells. Finally, silencing of SAMHD1 markedly increases the susceptibility of monocytic-derived dendritic cells to infection. Our results demonstrate that SAMHD1 is an antiretroviral protein expressed in cells of the myeloid lineage that inhibits an early step of the viral life cycle.

Most monocytic cell lines fail to recapitulate the HIV-1 restriction phenotype that is witnessed in primary dendritic cells and to a lesser extent in macrophages. One exception is represented by phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 monocytic cells^1,2,4-6. Transduction of differentiated THP-1 cells by virus-like particles containing Vpx (VLP-Vpx) has been shown to increase their permissiveness to HIV-1 infection¹. To identify the restriction factor targeted by Vpx, we generated a stable THP-1 cell line expressing Flag-HA epitope-tagged Vpx_mac251 from sooty mangabey (THP-1-Vpx). As expected, THP-1-Vpx cells were 17-fold more permissive to HIV-1 infection than parental cells when exposed to a vesicular stomatitis virus G protein (G)-pseudotyped HIV-1 with the luciferase gene in place of nef (HIV-LUC-G) (Supplementary Fig. 1). After differentiation, extracts were prepared from THP-1 and THP-1-Vpx cells. Flag-HA–Vpx_mac251 (F/H-Vpx) was purified using tandem affinity chromatography⁸. Purified Vpx_mac251-associated proteins were resolved by SDS–polyacrylamide gel electrophoresis (PAGE) and silver stained (Fig. 1a). The eluates were further analysed by mass spectrometry to allow for the identification of cellular partners that engage with Vpx_mac251 in non-permissive cells. Previously described Vpx_mac251 interactants were recovered, including the DDB1–CUL4–DCAF E3 ligase complex^9,10, confirming the validity of our approach. The SAM- and HD-domain-containing protein SAMHD1 was identified as a major Vpx_mac251-interacting protein (Table 1). SAMHD1 was initially isolated as an interferon (IFN)-γ-induced factor in macrophages and dendritic cells^11,12 for which a function in innate immunity has been suggested^7,13. Furthermore, mutations in SAMHD1 have been shown to be responsible for 5% of Aicardi–Goutières syndrome cases, a genetically heterogeneous disorder characterized by inappropriate activation of the immune system and aberrant IFN-α secretion, symptoms reminiscent of congenital infection⁷.

Figure 1

SAMHD1 interacts with Vpx and is degraded by the proteasome

Table 1

Major F/H-Vpx interactants identified by mass spectrometry

The interaction of SAMHD1 with Vpx_mac251 was confirmed by Flag-immunoprecipitation of F/H-Vpx and western blot analysis using a SAMHD1-specific antibody (Fig. 1b). Notably, analysis of whole-cell extracts of THP-1-Vpx as compared to THP-1 reveals that expression of Vpx_mac251 correlates with lower expression levels of SAMHD1 (Fig. 1b). Transient delivery of Vpx_mac251 into THP-1 cells through VLP-Vpx exposure caused a marked decrease in SAMHD1 levels in THP-1 cells (Fig. 1c). Moreover, treatment of cells with the proteasome inhibitor MG132 restored SAMHD1 protein levels (Fig. 1c), strongly suggesting that Vpx_mac251 induces proteasomal degradation of SAMHD1. Additionally, when SAMHD1 was expressed in HeLa cells, Vpx also caused its degradation, demonstrating that Vpx-induced degradation of SAMHD1 is not a cell-type-specific process and excluding a potential transcriptional effect of Vpx on SAMHD1 (Supplementary Fig. 2). These results led us to postulate that SAMHD1 may be the restriction factor that renders dendritic cells refractory to HIV-1 infection. Consistently, SAMHD1 is highly expressed in HIV-1 non-permissive cells such as THP-1, monocytes and monocyte-derived dendritic cells (MDDCs), whereas it is absent from HIV-1-sensitive T-cell lines such as Jurkat, SupT1, human peripheral blood acute lymphoid leukaemia (HPB-ALL) and U937 (Fig. 1d). In correlation with their degree of permissiveness to HIV-1 (refs 1, 4), monocyte-derived macrophages (MDMs) express low levels of SAMHD1 as compared to their highly refractory monocyte precursor (Fig. 1d).

It has been reported that Vpx-mediated enhancement of HIV-1 infection in dendritic cells and myeloid cells is conserved exclusively within the SIV_SM (sooty mangabey) and HIV-2 lineage (refs 1, 2 and Supplementary Fig. 2a). Concurrent with this observation, we show that Vpx_mac251 and HIV-2_ROD Vpx (Vpx_ROD) both caused degradation of SAMHD1, whereas Vpx from SIV_RCM of red-capped mangabeys (isolates of Nigerian (Vpx_RCM-NG) or Gabonese (Vpx_RCM-GAB) origin) failed to degrade SAMHD1 when expressed in THP-1 (Fig. 1e and Supplementary Fig. 3a, b) or HeLa cells (Supplementary Fig. 3c). Additionally, loss-of-function mutants Vpx(Q76A) and Vpx(F80A) also failed to degrade SAMHD1in differentiated THP-1 cells (Supplementary Fig. 3d).

To assess directly the impact of expression of SAMHD1 on HIV-1 infection, we used short hairpin RNAs (shRNA) to generate SAMHD1-silent THP-1 cells(THP-1-shSAMHD1) or scrambled shRNA (THP-1-scr) (Supplementary Fig. 4). Infection of THP-1-shSAMHD1 cells with HIV-LUC-G results in up to a 12-fold increase in luciferase activity as compared to THP-1-scr cells, demonstrating that depletion of SAMHD1 is sufficient to increase the permissiveness of THP-1 cells to HIV-1 infection (Fig. 2a). As expected, HIV-1 infection of THP-1-shSAMHD1 cells was not further enhanced by treatment with VLP-Vpx (Fig. 2b and Supplementary Fig. 5). Importantly, expression of a shRNA-resistant SAMHD1 mutant (SAMHD1-R) in THP-1-shSAMHD1 cells restored the restriction phenotype in these cells (Fig. 2d and Supplementary Fig. 6). To investigate further whether SAMHD1 possesses an intrinsic restriction activity targeting HIV-1, we stably expressed Flag-HA-tagged SAMHD1 (SAMHD1-F/H) in permissive U937 monocytic cells (U937-SAMHD1). Differentiated U937-SAMHD1 cells were 16-fold less permissive to infection with HIV-LUC-G than parental cells (Fig. 2e and Supplementary Fig. 8). HD domains have an important role in nucleotide metabolism through their nucleotidase and phosphodiesterase activities, where H and D residues are of crucial importance¹⁴. Interestingly, U937 cells stably expressing the SAMHD1(HD/AA) (U937-SAMHD1(HD/AA)) mutant did not show restriction activity towards HIV-1 as compared to U937-SAMHD1 cells, indicating that the putative phosphohydrolase activity of SAMHD1 may be required for restriction of HIV-1 (Fig. 2e and Supplementary Figs 7 and 8). Additionally, transient expression of SAMHD1-F/H, but not SAMHD1(HD/AA), in permissive HeLa cells induced restriction of HIV-1 infection (Supplementary Fig. 7).

Figure 2

SAMHD1 restricts HIV-1 infection in THP-1 cells

Vpx has been shown to facilitate HIV-1 replication by promoting accumulation of viral DNA^1,2,4,5,15. To investigate at which step of the viral replication cycle SAMHD1-dependent restriction operates, we quantified total viral DNA species 24 h after infection of THP-1-shSAMHD1 cells (Fig. 2f). A 13-fold accumulation of total viral DNA was observed in SAMHD1-silenced cells as compared to their THP-1-scr counterpart. This observation locates the restriction operated by SAMHD1 at the reverse transcription step, which has been previously described to be overcome by Vpx in dendritic and myeloid cells².

Exposure of differentiated THP-1, MDDCs and MDMs to VLP-Vpx relieves restriction to HIV-1 infection (Fig. 3a and Supplementary Fig. 9) and correlates with a decrease in SAMHD1 levels (Fig. 3b and Supplementary Fig. 9). Lower basal levels of SAMHD1 in primary MDMs (Fig. 1d) may be accountable for the weaker impact of VLP-Vpx treatment of these cells (Supplementary Fig. 9). Next, we asked whether SAMHD1 restricts HIV-1 infection of primary human dendritic cells. Immature MDDCs were prepared from the blood of four healthy donors. To silence SAMHD1 expression, we treated MDDCs with two different SAMHD1-specific siRNAs (si-SAMHD1-1 or si-SAMHD1-2). Scrambled or siRNA targeting dynamin 2 (siDYN2) were used as controls (Fig. 3c and Supplementary Fig. 10). MDDCs were transduced (at 48 h after silencing) with green-fluorescent-protein- or luciferase-encoding lentiviral vectors (LV-GFP or LV-LUC, respectively) or with a VSV-G-pseudotyped HIV (HIV-G). Silencing of SAMHD1 resulted in up to a 6-fold increase of GFP-positive cells with LV-GFP, 25-fold enhanced luciferase activity with LV-LUC, and up to 34-fold increased Gag-positive cells with HIV-G(Fig. 3d-f and Supplementary Fig. 10), demonstrating that SAMHD1 silencing in dendritic cells enhances their susceptibility to HIV-1 infection.

Figure 3

SAMHD1 restricts HIV-1 infection in primary MDDCs

So far, three restriction factors (TRIM5α, APOBEC-3G and tetherin) have been identified that could have constituted a major hindrance to HIV-1 replication, had the virus not developed ways to counteract or to escape their action^16-18. These restriction factors are part of the intrinsic immunity that is circumvented by HIV-1 mainly through the action of its auxiliary proteins. However, the cell-type-specific restriction factor SAMHD1 is not counteracted by HIV-1, resulting in poorly efficient replication in dendritic cells. Indeed, in the normal course of HIV-1 infection and because dendritic cells are non-permissive, these cells rather facilitate viral dissemination through trans-enhancement of infection, eventually favouring CD4⁺ T-cell depletion^19,20. Poor HIV-1 replication in dendritic cells may also allow for avoidance of a recently described cryptic viral sensor that would otherwise elicit antiviral interferon-induced immune responses^20,21. Similarly, in productively infected CD4⁺ T cells, through the action of the cellular DNase TREX1, HIV-1 avoids the induction of type 1 IFN production that could result from accumulation of viral DNA^20,22. Of note, both TREX1 and SAMHD1 deficiencies lead to Aicardi–Goutières syndrome, indicating that they have an impact on the same pathway of cell-intrinsic antiviral response⁷. SAMHD1, through the putative nucleotidase activity, may degrade or prevent accumulation of HIV DNA. It will be worth determining further the relative roles of TREX1 and SAMHD1 in the control of virus infection and in the triggering of innate antiviral and inflammatory responses.

Our findings position SAMHD1 as pivotal to the fate of infection by HIV-1 in cells of the myeloid lineage. Thus, modulating SAMHD1 function could render human hosts more prone to develop appropriate innate and adaptive immune responses^19,22-24. Our findings should be integrated in the development of dendritic-cell-targeted vaccines against HIV/AIDS.

METHODS

Cell lines

Adherent and suspension cells were cultured in DMEM or RPMI supplemented with 10% fetal calf serum (FCS), ultraglutamine and antibiotics. All cell culture reagents were purchased from Lonza. Cell lines expressing Flag- and HA-tagged proteins were constructed using the previously described MMLV-based retroviral constructs^8,26 that contain a bicistronic transcriptional unit allowing for expression of a selectable marker (IL-2 receptor-α chain (pOZ-IL2Rα) or puromycin resistance gene (pOZ-puro)). IL2Rα-selected cell lines were selected using magnetic beads. Puromycin-selected cell lines were cultured in appropriate media supplemented with 1 μg ml⁻¹ puromycin. shRNA-silenced cell lines were generated according to the manufacturer’s instructions (Openbiosystem) and selected for resistance to puromycin. U937 and THP-1 cells were differentiated overnight with 30 ng ml⁻¹ PMA (Sigma).

Plasmids

SIV3⁺ was a gift from N. Manel. HIV-LUC, VSV-G, MMLV packaging and A-MLV envelope have been previously described²⁷. shRNA constructs were purchased from Openbiosystem. Vpx_ROD, Vpx_RCM-NG and Vpx_RCM-GAB were synthesized by MWG biotech. The SAMHD1 molecular clone was purchased from Invitrogen. All Vpx_mac251, Vpx_ROD, Vpx_RCM-NG and Vpx_RCM-GAB were subcloned in pOZ-IL2Rα expression vector with tags at the N terminus, and SAMHD1 and SAMHD1 mutants were subcloned in pOZ-puro expression vector with tags at the C terminus according to standard ligation procedures. SAMHD1(HD/AA) and SAMHD1-R mutants were generated using the Quickchange lightning kit (Agilent technologies) according the manufacturer’s recommendations.

Virus production

Viral particles were produced from 293Tcells using the standard phosphate calcium transfection protocol. Briefly, for HIV-LUC-G production, 293T cells were transfected with 8 μg HIV-LUC and 2 μg VSV-G encoding plasmid; for shRNA production, 293T cells were transfected with 4 μg shRNA construct, 4 μg packaging plasmid, 2 μg VSV-G encoding plasmid; for MLV transduction particles, 293T cells were transfected with 5 μg pOZ construct, 2.5 μg packaging plasmid and 2.5 μg A-MLV envelope encoding plasmid; and for VLP-Vpx production, 8 μg SIV3⁺ was co-transfected or not with 2 μg VSV-G encoding plasmid. Media was replaced 16 h after transfection and viruses were harvested 24 h later, filtered at 0.45 μm. When required, p24 concentration was measured by ELISA (Innogenetics).

Infection

Infection of THP-1, U937 and HeLa cells was performed by addition of 100, 50, 10, 5 or 1 ng p24 of HIV-LUC-G depending on the experiment. Viruses were added to cells and luciferase activity was measured 24 h after infection. VLP-Vpx treatment was performed for 2 h before infection by addition of RPMI-diluted VLP-Vpx to cells.

Cell extract preparation and western blot analysis

Whole-cell extracts were prepared with buffer containing 0.5% Triton X-100, 150 mM NaCl, 10 mM KCL, 1.5 mM MgCl₂, 0.5 mM EDTA 10 mM β-mercaptoethanol, 0.5 mM PMSF. Mouse anti-SAMHD1, anti-CUL4A and anti-DDB1 were purchased from Abcam. HA (11 clone 16B12) and tubulin antibodies were from Covance/Eurogentec and Sigma, respectively.

Immunopurification

Vpx_mac251 was purified from 5 × 10⁹ differentiated THP-1 cells stably expressing Flag- and HA-tagged Vpx_mac251 (F/H-Vpx) by two-step affinity chromatography according to the standard method⁸. Extracts were first incubated with anti-Flag antibody conjugated agarose beads (Sigma), and the bound polypeptides were eluted with Flag peptide (Sigma) under native conditions. The Flag affinity-purified material was further immunopurified by affinity chromatography using anti-HA antibody conjugated agarose beads (Santa Cruz) and eluted under native conditions using HA peptide (Roche). Five per cent of immunoaffinity-purified F/H-Vpx or mock were resolved on SDS-PAGE and stained with the Silverquest kit (Invitrogen). The remainder of the eluate was stained with colloidal blue. Individual Coomassie-stained bands, or for closely migrating bands, regions of the gel were excised and subsequently analysed by tandem mass spectrometry at the Harvard Medical School Taplin Biological Mass Spectrometry facility.

Quantification of HIV-1 total DNA

Before infection, viral stocks were treated for 1 h at 37 °C with 100 U ml⁻¹ of DNaseI (Roche). 3 × 10⁵ THP-1-scr or THP-1-shSAMHD1 cells were infected with 100 ng of HIV-LUC-Gor with heat-inactivated HIV-LUC-G. Cells were washed twice in PBS 2 h after infection, harvested 22 h later, washed twice in PBS, and DNA was extracted using the QIAamp Blood DNA Minikit (Qiagen). Quantification of viral DNA was performed by quantitative PCR (qPCR) using previously described probes²⁷ allowing for amplification of the luciferase gene on a LightCycler 480 system (Roche). Viral DNA was normalized using 7SK-specific probes.

Preparation of MDDCs and MDMs

Human buffy coats were obtained from Etablissement Français du Sang (EFS). Monocytes were purified from total peripheral blood mononuclear cells after Ficoll gradient separation with CD14 MicroBeads (Miltenyi Biotec) or using the standard adhesion protocol. Human monocyte-derived dendritic cells (MDDCs) were generated by incubation of CD14 purified monocytes in IMDM medium supplemented with 10% FCS, 2 mM l-glutamine, 100 IU ml⁻¹ penicillin, 100 mg ml⁻¹ streptomycin, 10 mM HEPES, 1% non-essential amino acids, 1 mM sodium pyruvate, 10 ng ml⁻¹ GM-CSF and 50 ng ml⁻¹ IL-4 (Miltenyi Biotec). On day 4, two-thirds of the culture medium was replaced by fresh medium containing GM-CSF and IL-4. Immature MDDCs (iDCs) were harvested and further used at day 6.

MDMs were generated by 7 days of stimulation with 50 ng ml⁻¹ of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) (Immunotools).

Efficient differentiation of MDM and MDDCs was verified by flow cytometry using antibodies against CD1a, CD14, CD80, CD83 (BD Bioscience) and CD86 (B72 clone, Invitrogen). MDDCs were more than 98% DC-SIGN positive.

siRNA transfection of MDDCs

scrambled siRNA, siSAMHD1-1 (5′-GAUUCAUUGUGGCCAUAUA-3′) and siSAMHD1-3 (5′-CAACCAGAGCUGCAGAUAA-3′) were synthesized by MWGoperon. siDYN2 was from Qiagen. HiPerFect Reagent (Qiagen) was used for transfection in accordance with the manufacturer’s recommendations. In brief, 5 × 10⁵ iDCs were transfected with 100 nM siRNA in 500 ml of IMDM/1% FCS medium in 12-well plates. A second round of transfection was performed 24 h later. Specific gene knockdowns were assessed by immunoblot.

Transduction of MDDCs

One day after the second round of silencing, MDDCs were transduced with a lentiviral vector expressing the GFP or luciferase gene (LV-GFP and LV-LUC, respectively) or VSV-G-pseudotyped HIV (HIV-G). Briefly, 2.5 × 10⁵ MDDCs were seeded in 24-well plates and exposed to the indicated doses of lentiviral vectors or HIV-G (from 1 to 100 ng p24 per ml). After overnight incubation, the medium was replaced with fresh medium containing GM-CSF and IL-4. Four days after transduction, GFP or p24 expression was analysed by flow cytometry using a FacsCalibur (Becton Dickinson) with FlowJo software or luciferase activity was measured using a Mithras luminometer (Berthold technologies).

Supplementary Material

supporting info

Click here to view.^{(392K, pdf)}

Acknowledgements

We wish to thank members of the Molecular Virology laboratory for critical reading of the manuscript, N. Manel for SIV3⁺ molecular clone and J. Luban for SIV delta Vpx and Vpx mutants. This work was supported by grants from the ERC (250333), Sidaction, ANRS and FRM ’équipe labéllisée’ to M.B. N.L was supported by ANRS and SIDACTION fellowships; B.S. by ANRS fellowship; M.R. by CNRS/région Languedoc Roussillon fellowship. O.S. and N.C. are supported by grants from ANRS, Sidaction, ANR, European FP7 contract 201412 and Institut Pasteur.

Footnotes

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

The authors declare no competing financial interests.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

References

1. Goujon C, et al. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J. Virol. 2008;82:12335–12345. [PMC free article] [PubMed]

2. Goujon C, et al. SIV_SM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology. 2007;4:2. [PMC free article] [PubMed]

3. Hirsch VM, et al. Vpx is required for dissemination and pathogenesis of SIV_SM PBj: evidence of macrophage-dependent viral amplification. Nature Med. 1998;4:1401–1408. [PubMed]

4. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M. A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe. 2009;6:68–80. [PMC free article] [PubMed]

5. Sharova N, et al. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog. 2008;4:e1000057. [PMC free article] [PubMed]

6. Ayinde D, Maudet C, Transy C, Margottin-Goguet F. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology. 2010;7:35. [PMC free article] [PubMed]

7. Rice GI, et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nature Genet. 2009;41:829–832. [PubMed]

8. Nakatani Y, Ogryzko V. Immunoaffinity purification of mammalian protein complexes. Methods Enzymol. 2003;370:430–444. [PubMed]

9. Bergamaschi A, et al. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J. Virol. 2009;83:4854–4860. [PMC free article] [PubMed]

10. Srivastava S, et al. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog. 2008;4:e1000059. [PMC free article] [PubMed]

11. Li N, Zhang W, Cao X. Identification of human homologue of mouse IFN-γ induced protein from human dendritic cells. Immunol. Lett. 2000;74:221–224. [PubMed]

12. Liao W, Bao Z, Cheng C, Mok YK, Wong WS. Dendritic cell-derived interferon-γ-induced protein mediates tumor necrosis factor-α stimulation of human lung fibroblasts. Proteomics. 2008;8:2640–2650. [PubMed]

13. Zhao D, Peng D, Li L, Zhang Q, Zhang C. Inhibition of G1P3 expression found in the differential display study on respiratory syncytial virus infection. Virol. J. 2008;5:114. [PMC free article] [PubMed]

14. Zimmerman MD, Proudfoot M, Yakunin A, Minor W. Structural insight into the mechanism of substrate specificity and catalytic activity of an HD-domain phosphohydrolase: the 5′-deoxyribonucleotidase YfbR from Escherichia coli. J. Mol. Biol. 2008;378:215–226. [PMC free article] [PubMed]

15. Gramberg T, Sunseri N, Landau NR. Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx. J. Virol. 2010;84:1387–1396. [PMC free article] [PubMed]

16. Stremlau M, et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–853. [PubMed]

17. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. [PubMed]

18. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451:425–430. [PubMed]

19. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nature Rev. Immunol. 2011;11:176–186. [PMC free article] [PubMed]

20. Yan N, Lieberman J. Gaining a foothold: how HIV avoids innate immune recognition. Curr. Opin. Immunol. 2011;23:21–28. [PMC free article] [PubMed]

21. Manel N, et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. 2010;467:214–217. [PMC free article] [PubMed]

22. Borrow P, Shattock RJ, Vyakarnam A. Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology. 2010;7:84. [PMC free article] [PubMed]

23. Cobb A, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J. Immunol. Methods. 2011;365:27–37. [PubMed]

24. Lepelley A, et al. Innate sensing of HIV-infected cells. PLoS Pathog. 2011;7:e1001284. [PMC free article] [PubMed]

25. Blanchet FP, et al. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity. 2010;32:654–669. [PMC free article] [PubMed]

26. Kumar D, Shadrach JL, Wagers AJ, Lassar AB. Id3 is a direct transcriptional target of Pax7 in quiescent satellite cells. Mol. Biol. Cell. 2009;20:3170–3177. [PMC free article] [PubMed]

27. Sobhian B, et al. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol. Cell. 2010;38:439–451. [PMC free article] [PubMed]